Keyphrases
Peru
100%
Cost-effectiveness
100%
Cetuximab
100%
Metastatic Colorectal Cancer (mCRC)
100%
Treatment Strategy
100%
Chemotherapy
100%
Chemotherapy Alone
100%
Quality-adjusted Life Years
42%
GDP per Capita
42%
Early Tumor Shrinkage
28%
Ministry of Health
14%
Markov Model
14%
Health Status
14%
Incremental Cost-effectiveness Ratio
14%
Combination Treatment
14%
R0 Resection
14%
Disease Progression
14%
Conventional Chemotherapy
14%
Local Perspectives
14%
Clinical Significance
14%
Probabilistic Analysis
14%
Progression-free Survival
14%
Metastases Resection
14%
To Determine the Effectiveness
14%
Economic Model
14%
Progressive Disease
14%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Cetuximab
100%
Metastatic Colon Cancer
100%
Health Care Cost
57%
Head
42%
Quality Adjusted Life Year
42%
Neoplasm
28%
Progressive Disease
14%
Metastasectomy
14%
Health Status
14%
Disease Exacerbation
14%
Surgery
14%
Progression Free Survival
14%
Systematic Review
14%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Cetuximab
100%
Metastatic Colon Cancer
100%
Quality Adjusted Life Year
42%
Neoplasm
28%
Systematic Review
14%
Health Status
14%
Metastasis Resection
14%
Surgery
14%
Disease Exacerbation
14%
Disease
14%
Progression Free Survival
14%
Incremental Cost-Effectiveness Ratio
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cetuximab
100%
Chemotherapy
100%
Metastatic Colon Cancer
100%
Neoplasm
28%
Disease
14%
Health Status
14%
Progression Free Survival
14%
Disease Exacerbation
14%